Role of CD47 in Hematological Malignancies

Manipulation of the Innate Immune Response by Varicella Zoster Virus

(2020) Chelsea Gerada et al.   Frontiers in Immunology

Targeting CD47 as a Novel Immunotherapy for Multiple Myeloma

(2020) Jennifer Sun et al.   Cancers

Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies

(2020) Mark P. Chao et al.   Frontiers in Oncology

Simultaneous blocking of CD47 and PD-L1 increases innate and adaptive cancer immune responses and cytokine release

(2019) Shu Lian et al.   EBioMedicine

Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPα axis and a target for cancer immunotherapy

(2019) Meike E. W. Logtenberg et al.   NATURE MEDICINE

Discovery of high affinity, pan-allelic, and pan-mammalian reactive antibodies against the myeloid checkpoint receptor SIRPα

(2019) Janet Sim et al.   mAbs

Programmable bacteria induce durable tumor regression and systemic antitumor immunity

(2019) Sreyan Chowdhury et al.   NATURE MEDICINE

The effects of monoclonal anti‐CD47 on RBCs, compatibility testing, and transfusion requirements in refractory acute myeloid leukemia

(2019) C.K. Brierley et al.   TRANSFUSION

PKHB1 Tumor Cell Lysate Induces Antitumor Immune System Stimulation and Tumor Regression in Syngeneic Mice with Tumoral T Lymphoblasts

(2019) Ana Carolina Martínez-Torres et al.   Journal of Oncology

Targeted Inhibition of CD47-SIRPα Requires Fc-FcγR Interactions to Maximize Activity in T-cell Lymphomas

(2019) Salvia Jain et al.   BLOOD

CD47: role in the immune system and application to cancer therapy

(2019) Seyed Mohammad Gheibi Hayat et al.   CELLULAR ONCOLOGY

Anti-CD47 Antibody, CC-90002, in Combination with Rituximab in Subjects with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL)

(2019) Pau Abrisqueta et al.   BLOOD

Targeting CD47/TNFAIP8 by miR-155 overcomes drug resistance and inhibits tumor growth through induction of phagocytosis and apoptosis in multiple myeloma

(2019) Nasrin Rastgoo et al.   HAEMATOLOGICA

CD47-signal regulatory protein α signaling system and its application to cancer immunotherapy

(2018) Yoji Murata et al.   CANCER SCIENCE

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

(2018) Rosemarie Tremblay-LeMay et al.   Journal of Hematology & Oncology

MicroRNA-494 promotes cancer progression and targets adenomatous polyposis coli in colorectal cancer

(2018) Ying Zhang et al.   Molecular Cancer

Preclinical development of a bispecific antibody that safely and effectively targets CD19 and CD47 for the treatment of B cell lymphoma and leukemia

(2018) Vanessa Buatois et al.   MOLECULAR CANCER THERAPEUTICS

Combination of anthracyclines and anti-CD47 therapy inhibit invasive breast cancer growth while preventing cardiac toxicity by regulation of autophagy

(2018) Yismeilin R. Feliz-Mosquea et al.   BREAST CANCER RESEARCH AND TREATMENT

Abstract 2709: TTI-622 (SIRPα-IgG4 Fc), a CD47-blocking innate immune checkpoint inhibitor, suppresses tumor growth and demonstrates enhanced efficacy in combination with antitumor antibodies in both hematologic and solid tumor models

(2018) Gloria H. Y. Lin et al.   CANCER RESEARCH

Abstract 5623: Development of a CD47-blocking antibody as a cancer therapy

(2018) Joshua Oaks et al.   CANCER RESEARCH

ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile

(2018) Steven E. Kauder et al.   PLoS One

In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment

(2018) Qian Chen et al.   Nature Nanotechnology

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma

(2018) Ranjana Advani et al.   NEW ENGLAND JOURNAL OF MEDICINE

Expression and significance of CD47, PD1 and PDL1 in T-cell acute lymphoblastic lymphoma/leukemia

(2018) Kun Yang et al.   PATHOLOGY RESEARCH AND PRACTICE

A Raman Imaging Approach Using CD47 Antibody-Labeled SERS Nanoparticles for Identifying Breast Cancer and Its Potential to Guide Surgical Resection

(2018) Ryan Davis et al.   Nanomaterials

Cancer immunotherapy targeting the CD47/SIRPα axis

(2017) Kipp Weiskopf   EUROPEAN JOURNAL OF CANCER

Mithramycin-loaded mPEG-PLGA nanoparticles exert potent antitumor efficacy against pancreatic carcinoma

(2017) Xu-Jie Liu et al.   International Journal of Nanomedicine

Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses

(2017) Boning Liu et al.   mAbs

Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity

(2017) Nan Guo Ring et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Selinexor Overcomes Hypoxia-Induced Drug Resistance in Multiple Myeloma

(2017) Barbara Muz et al.   Translational Oncology

Anti-leukemic activity and tolerability of anti-human CD47 monoclonal antibodies

(2017) E C Pietsch et al.   Blood Cancer Journal

SIRPα-antibody fusion proteins stimulate phagocytosis and promote elimination of acute myeloid leukemia cells

(2017) Laia Pascual Ponce et al.   Oncotarget

Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies

(2017) Pauline Gravelle et al.   Oncotarget

SIRP -Antibody Fusion Proteins Selectively Bind and Eliminate Dual Antigen-Expressing Tumor Cells

(2016) E. C. Piccione et al.   CLINICAL CANCER RESEARCH

TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding

(2016) Penka S. Petrova et al.   CLINICAL CANCER RESEARCH

Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway

(2016) Vassiliki A. Boussiotis   NEW ENGLAND JOURNAL OF MEDICINE

Durable antitumor responses to CD47 blockade require adaptive immune stimulation

(2016) Jonathan T. Sockolosky et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

MYC regulates the antitumor immune response through CD47 and PD-L1

(2016) S. C. Casey et al.   SCIENCE

“Velcro” Engineering of High Affinity CD47 Ectodomain as Signal Regulatory Protein α (SIRPα) Antagonists That Enhance Antibody-dependent Cellular Phagocytosis

(2015) Chia Chi M. Ho et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells

(2015) Emily C Piccione et al.   mAbs

Efficacy of anti-CD47 antibody-mediated phagocytosis with macrophages against primary effusion lymphoma

(2014) Hiroki Goto et al.   EUROPEAN JOURNAL OF CANCER

The CD47-SIRP  signalling system: its physiological roles and therapeutic application

(2014) Y. Murata et al.   JOURNAL OF BIOCHEMISTRY

Intravenous Delivery of siRNA Targeting CD47 Effectively Inhibits Melanoma Tumor Growth and Lung Metastasis

(2013) Yuhua Wang et al.   MOLECULAR THERAPY

CD47 update: a multifaceted actor in the tumour microenvironment of potential therapeutic interest

(2012) E Sick et al.   BRITISH JOURNAL OF PHARMACOLOGY

Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells

(2012) D Kim et al.   LEUKEMIA

CD47 expression regulated by the miR-133a tumor suppressor is a novel prognostic marker in esophageal squamous cell carcinoma

(2012) SHIGEMASA SUZUKI et al.   ONCOLOGY REPORTS

The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors

(2012) S. B. Willingham et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy

(2011) M. P. Chao et al.   BLOOD

The CD47 pathway is deregulated in human immune thrombocytopenia

(2011) Lucia Catani et al.   EXPERIMENTAL HEMATOLOGY

The Thrombospondins

(2011) J. C. Adams et al.   Cold Spring Harbor Perspectives in Biology

Therapeutic Antibody Targeting of CD47 Eliminates Human Acute Lymphoblastic Leukemia

(2010) Mark P. Chao et al.   CANCER RESEARCH

Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma

(2010) Mark P. Chao et al.   CELL

Thrombospondin-1 Inhibits VEGF Receptor-2 Signaling by Disrupting Its Association with CD47

(2010) Sukhbir Kaur et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Dominant role of CD47-thrombospondin-1 interactions in myeloma-induced fusion of human dendritic cells: implications for bone disease

(2009) A. Kukreja et al.   BLOOD

CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis

(2009) Siddhartha Jaiswal et al.   CELL

CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells

(2009) Ravindra Majeti et al.   CELL

CD47 Regulates Collagen I-Induced Cyclooxygenase-2 Expression and Intestinal Epithelial Cell Migration

(2009) Oliver Jay Broom et al.   PLoS One

Differential Interactions of Thrombospondin-1, -2, and -4 with CD47 and Effects on cGMP Signaling and Ischemic Injury Responses

(2008) Jeff S. Isenberg et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Inhibition of “self” engulfment through deactivation of myosin-II at the phagocytic synapse between human cells

(2008) Richard K. Tsai et al.   JOURNAL OF CELL BIOLOGY

Paired Receptor Specificity Explained by Structures of Signal Regulatory Proteins Alone and Complexed with CD47

(2008) Deborah Hatherley et al.   MOLECULAR CELL

CD47 associates with alpha 5 integrin and regulates responses of human articular chondrocytes to mechanical stimulation in an in vitro model

(2008) Mahmoud Orazizadeh et al.   ARTHRITIS RESEARCH & THERAPY